Green cross‘ new drug see the light of day
Green cross‘ new drug see the light of day
  • Healthkoreanews
  • 승인 2010.02.11 10:41
  • 댓글 0
이 기사를 공유합니다

[헬스코리아뉴스]The U.S. Food and Drug Administration(FDA) accepted the IND(Investigational New Drug) application for 'GCC1290K' which Green cross has been developing as new drug for treatment of Parkinson's disease.

Parkinson's disease is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.

According to Kim Jung-Min, managing director of Green cross, 'GCC1290K' has shown its safety and effectiveness, successfully passing the animal testing phase, and it can also treat some side effects of conventional drugs.

This is the first time that the FDA accepted the IND application for a drug under development by purely domestic technology for the treatment of patients with Parkinson's disease.

Green cross has applied for patents on the chemicals substances and purpose of the drug in 16 countries including U.S.A and Europe.

[원문 기사]

美 FDA, 녹십자 파킨슨병 신약 임상시험 승인

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

      편집자 추천 뉴스
      베스트 클릭
      오늘의 단신